Table of Contents
. Number of total observations and litters represented in mixed effect models (observations, litters) . Table S2 . Internal dosimetry of tissues at embryonic day 11.5 including maternal serum, maternal liver, amniotic fluid, and whole embryo (Mean ± SD, N = 6-8). Table S3 . Internal dosimetry of tissues at embryonic day 17.5 including maternal serum, maternal liver, male whole embryo and female whole embryo (Mean ± SD, N = 6-8). Table S4 . Litter parameters in mice gestationally exposed to PFOA or GenX from embryonic day 0.5 to 11.5 or 17.5 (Mean ± SD, . Table S5 . Relative gestational weight gain (% gain from embryonic day 0.5) at necropsy adjusting for litter size (adjusted model estimate and 95% confidence intervals; N = 11-13). Table S6 . Incidence of liver histopathology in maternal livers at embryonic day 11.5. Table S7 . Incidence of liver histopathology in maternal livers at embryonic day 17.5. Table S8 . Embryo and placental mixed effect model adjusted estimates and 95% confidence intervals (N = 11-13 dams with 62-80 observations per group). Table S9 . Placental lesion index at embryonic day 11.5. Table S10 . Placental lesion incidence at embryonic day 17.5. Table S11 . Sex stratified placental thyroid hormone measurements at embryonic day 17.5 (Mean ± SD, N = 1-3). Figure S1 . Representative examples of liver histology in pregnant dams at gestation days 11.5 and 17.5 exposed to either vehicle control (A, B, C, D) or treated with GenX (also HFPO-DA; E, F) or PFOA (G, H). (A) Liver from a pregnant dam at 11.5 days of gestation, exposed to vehicle control (4X). (B) Higher magnification of (A) illustrating the normal uniform hepatocellular size and cytoplasmic glycogen accumulation (20X). (C) Example of a liver from a pregnant dam at 17.5 days of gestation, exposed to vehicle control. The features of centrilobular hepatocellular hypertrophy (arrows), karyomegaly, increased mitotic figures, decreased glycogen, and increased basophilic granular cytoplasm are normal features for dam livers at this stage of pregnancy (4X). (D) Higher magnification of (C) illustrating the increased mitotic figures (arrow) decreased glycogen, and increased basophilic granular cytoplasm in the areas of centrilobular hepatocellular hypertrophy (20X). (E) Example of a liver from a pregnant dam at 11.5 days of gestation, exposed to 10 mg/kg/day of GenX. There is diffuse moderate cytoplasmic alteration in this liver affecting the centrilobular, midzonal and periportal regions (4X). (F) Higher magnification of (E) illustrating the hepatocellular hypertrophy with decreased glycogen and eosinophilic granular cytoplasm. The arrows show examples of early hepatocellular apoptosis with condensed cytoplasm and condensed dark basophilic nuclear chromatin (20X). (G) Example of a liver from a pregnant dam at gestation day 17.5, exposed to 5 mg/kg/day PFOA with diffuse cytoplasmic alteration (4X). (H) Higher magnification of the boxed region in (G) showing cytoplasmic alteration with apoptosis (arrowheads) as well as accumulation of hepatocellular cytoplasmic small vacuoles with distinct borders (arrow; 20X). Figure S3 . Representative examples of occasional histopathological placenta findings observed in dams at gestation day 17.5. (A) Early clot formation in a maternal artery in the decidua region of the placenta (20X). This dam was at gestation day 17.5 and treated with 10 mg/kg/day GenX (also HFPO-DA). Note the fibrin formation with trapped cells. (B) Nodule (arrow) of tissue from the junction zone of the placenta from a dam at gestational day 17.5 that was treated with 2 mg/kg/day GenX (2X). Figure S4 . Comparison of maternal serum or plasma levels (mean ± SD) in CD-1 mice gestationally exposed to GenX (also HFPO-DA) at varying dose levels in a study conducted by DuPont-18405-1037 (Edwards 2010b; plasma measured on lactation day 21) and the present study (Blake et al. 2019 ; serum measured on E17.5). Maternal serum or plasma was collected less than 6 hours after oral gavage in both studies. Administered GenX dose and maternal serum or plasma concentration was linearly correlated across data from both studies (R 2 = 0.959, P < 0.05 for non-zero slope). 3.21 ± 0.51 † † ANOVA with post hoc multiple comparison correction using Tukey contrasts: * P < 0.05 1 mg/kg/day PFOA vs 5 mg/kg/day PFOA † P < 0.05 1 mg/kg/day PFOA vs 2 mg/kg/day GenX ‡ P < 0.05 1 mg/kg/day PFOA vs 10 mg/kg/day GenX § P < 0.05 2 mg/kg/day GenX vs 5 mg/kg/day PFOA ** P < 0.05 2 mg/kg/day GenX vs 10 mg/kg/day GenX † † P < 0.05 10 mg/kg/day GenX vs 5 mg/kg/day PFOA Note: Vehicle control (VC) samples were quantified for PFOA and GenX (HFPO-DA); all VC means were below the limit of detection (LOD) of 10 ng/mL for both PFOA and GenX (HFPO-DA) Table S3 . Internal dosimetry of tissues at embryonic day 17.5 including maternal serum, maternal liver, male whole embryo and female whole embryo (Mean ± SD, N = 6-8) 3.39 ± 1.44 §,** 6.89 ± 2.72 † † ANOVA with post hoc multiple comparison correction using Tukey contrasts: * P < 0.05 1 mg/kg/day PFOA vs 5 mg/kg/day PFOA † P < 0.05 1 mg/kg/day PFOA vs 2 mg/kg/day GenX ‡ P < 0.05 1 mg/kg/day PFOA vs 10 mg/kg/day GenX § P < 0.05 2 mg/kg/day GenX vs 5 mg/kg/day PFOA ** P < 0.05 2 mg/kg/day GenX vs 10 mg/kg/day GenX † † P < 0.05 10 mg/kg/day GenX vs 5 mg/kg/day PFOA Note: N = 3 for PFOA 5 mg/kg male embryo; Vehicle control (VC) samples were quantified for PFOA and GenX (HFPO-DA); all VC means were below the LOD of 10 ng/mL for both PFOA and GenX (HFPO-DA) except for maternal serum (0.211 ± 0.55 µg/mL) Table S4 . Litter parameters in mice gestationally exposed to PFOA or GenX from embryonic day 0.5 to 11.5 or 17.5 (Mean ± SD, N = 11-13) Embryonic day Litter parameter Vehicle Control 1 mg/kg bw/day PFOA 5 mg/kg bw/day PFOA 2 mg/kg bw/day GenX (HFPO-DA) 10 mg/kg bw/day GenX (HFPO-DA) 11.5
No. implantation sites 13.7 ± 2.8 15.5 ± 2.7 14.5 ± 2.3 14.7 ± 2.7 14.8 ± 3.7 11.5
No. resorptions 0.6 ± 1.1 0.6 ± 0.5 0.5 ± 0.9 0.7 ± 0.8 0.9 ± 1.3 11.5
No. dead embryos
No. viable embryos 13.1 ± 3.0 14.8 ± 2.5 13.9 ± 2.2 14.0 ± 2.9 13.8 ± 3.7 11.5 % resorbed † 4.6 ± 8.6 4.0 ± 3.3 3.6 ± 5.9 5.0 ± 6.2 5.6 ± 7.7 11.5 % nonviable † 0.0 ± 0.0 0.0 ± 0.0 0.6 ± 1.9 0.0 ± 0.0 2. 0 (0) 0 (0) 0 (0) 0 (0) 5 (100) Vacuolation, mild 0 (0) 0 (0) 5 (100) 0 (0) 0 (0) Vacuolation, moderate 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) Abbr: CA = cytoplasmic alteration *CA was characterized as hepatocellular hypertrophy with decreased glycogen and intensely eosinophilic granular cytoplasm, with extension from periportal to midzonal regions with increasing severity † Cell death included both apoptosis and single cell necrosis of individual hepatocytes ‡ Vacuolation was graded by severity based on occurrence of clear, small, and round vacuoles in the cytoplasm of centrilobular hepatocytes in areas of cytoplasmic alteration as: minimal-rarely or occasionally seen as small clusters; mild-frequently seen as small clusters; moderate-seen in all centrilobular hepatocytes Note: Histopathology was evaluated by a pathology working group and observations of increased mitotic figures and cell death were made relative to the vehicle control group; increase in mitotic figures and cell death was scored as minimal 10 mg/kg/day GenX (HFPO-DA) Lesion type and severity N (%) N (%) N (%) N (%) N (%) CA*, any severity 0 (0) 5 (100) 6 (100) 5 (100) 5 (100) CA, minimal to mild 0 (0) 0 (0) 0 (0) 2 (40) 0 (0) CA, moderate 0 (0) 5 (100) 0 (0) 3 (60) 0 (0) CA, marked 0 (0) 0 (0) 6 (100) 0 (0) 5 (100) Increase in mitotic figures 5 (100) 0 (0) 0 (0) 0 (0) 0 (0) Increase in cell death † 0 (0) 5 (100) 6 (100) 0 (0) 5 (100) Focal regions of classic necrosis 0 (0) 0 (0) 0 (0) 1 (20) 1 (20) Vacuolation ‡ , any severity 0 (0) 0 (0) 6 (100) 0 (0) 5 (100) Vacuolation, minimal 0 (0) 0 (0) 0 (0) 0 (0) 2 (40) Vacuolation, mild 0 (0) 0 (0) 0 (0) 0 (0) 3 (60) Vacuolation, moderate 0 (0) 0 (0) 6 (100) 0 (0) 0 (0) Abbr: CA = cytoplasmic alteration *CA was characterized as hepatocellular hypertrophy with decreased glycogen and intensely eosinophilic granular cytoplasm, with extension from periportal to midzonal regions with increasing severity † Cell death included both apoptosis and single cell necrosis of individual hepatocytes ‡ Vacuolation was graded by severity based on occurrence of clear, small, and round vacuoles in the cytoplasm of centrilobular hepatocytes in areas of cytoplasmic alteration as: minimal-rarely or occasionally seen as small clusters; mild-frequently seen as small clusters; moderate-seen in all centrilobular hepatocytes Note: Histopathology was evaluated by a pathology working group and observations of increased mitotic figures and cell death were made relative to the vehicle control group; increase in mitotic figures and cell death was scored as minimal 
3) 0 (0) No. litters evaluated 5 5 5 5 5 Mean no. placenta evaluated per litter (min, max) 7.4 (5, 10) 6.6 (4, 10) 7.4 (5, 10) 8.6 (4, 11) 6.2 (3, 11)
Mean WNL ± SD (%) per litter 6.4 ± 1.9 (95.0) 6.4 ± 1.9 (98.0) 6.4 ± 1.7 (88.3) 8.2 ± 2.8 (95.6) 6.0 ± 3.1 (97.1) Mean abnormal ± SD (%) per litter 0.4 ± 0.9 (5.0) 0.2 ± 0.4 (2.0) 1.0 ± 1.4 (11.7) 0.4 ± 0.9 (4.4) 0 ± 0.0 (0) Abbr: WNL = within normal limits *P < 0.05 relative to vehicle control (general linear model using a Poisson distribution with post hoc multiple comparison correction using Tukey contrasts) † Other lesions were considered spontaneous and not treatment related and included: Increased thickness of trilaminar trophoblast layers (vehicle control), decreased labyrinth area (vehicle control), absent labyrinth (PFOA 1 mg/kg), large focal labyrinth hemorrhage and thrombus (GenX 2 mg/kg) Abbr: rT3 = reverse triiodothyronine, T3 = triiodothyronine, T4 = thyroxine, MDL = method detection limit Note: P > 0.05 relative to vehicle control for all values including sex*treatment as an interaction term in the model (ANOVA with post hoc multiple comparison correction using Tukey contrasts); Sample sizes ranged from N = 1-3; Non-quantifiable samples below the MDL were imputed using the calculation MDL*0.5. MDL values were: T4: 0.84 ng/g, T3: 0.42 ng/g, rT3: 0.67 ng/g. Figure S2 . Transmission electron microscopy (TEM) of normal liver and livers exposed to PFOA or GenX (also HFPO-DA). This dam was at gestation day 17.5 and treated with 10 mg/kg/day GenX (also HFPO-DA). Note the fibrin formation with trapped cells. (B) Nodule (arrow) of tissue from the junction zone of the placenta from a dam at gestational day 17.5 that was treated with 2 mg/kg/day GenX (2X). Figure S4 . Comparison of maternal serum or plasma levels (mean ± SD) in CD-1 mice gestationally exposed to GenX (also HFPO-DA) at varying dose levels in a study conducted by DuPont-18405-1037 (Edwards 2010b; plasma measured on lactation day 21) and the present study (Blake et al. 2019; serum measured on E17.5). Maternal serum or plasma was collected less than 6 hours after oral gavage in both studies. Administered GenX dose and maternal serum or plasma concentration was linearly correlated across data from both studies (R 2 = 0.959, P < 0.05 for non-zero slope).
